# Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder

> **NCT01564862** · PHASE2 · COMPLETED · sponsor: **Takeda** · enrollment: 602 (actual)

## Conditions studied

- Depressive Disorder, Major

## Interventions

- **DRUG:** vortioxetine (Lu AA21004)
- **DRUG:** Duloxetine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01564862
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 602 (ACTUAL)
- **Last updated:** 2015-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01564862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01564862, "Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01564862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*